|[May 09, 2014]
BayBio Names Henry M. Gunn High School Senior Amgen Bay Area BioGENEius Finalist
SOUTH SAN FRANCISCO, Calif. --(Business Wire)--
BayBio today named Henry M. Gunn High School senior Emily Wang of Palo
Alto as the winner of the 2014 Amgen Bay Area BioGENEius Challenge, the
premier competition for high school students that recognizes outstanding
research in biotechnology. As the Amgen Bay Area BioGENEius finalist,
Wang will gain insider access to the biotechnology industry by attending
the 2014 BIO International Convention in San Diego, the industry's trade
conference, where leading companies, scientists and innovators will
offer her invaluable advice and first-hand experience on the limitless
possibilities within one of the world's most innovative industries.
While in San Diego, Wang will compete against students from the U.S. and
Canada in the International BioGENEius Challenge. Folsom High School
Junior Nathaniel Varghese placed second and Bellarmine College
Preparatory sophomore Anin Sayana placed third.
Vinay Ayyappan (Bellarmine College Preparatory), Raghu Dhara (Mission
San Jose School) and Gokul Kalyanasundaram (Homestead High School)
received honorable mentions by the judges.
"The Challenge is a leading example of an educational experience that
provides students with the biotechnology skills and knowledge needed to
succeed in this field," said Lori Lindburg, executive director of the
BayBio Institute. "This June, BayBio will be cheering on Emily Wang at
the 2014 BIO International Convention as we already know that her
current and future research has an opportunity to make a noteworthy
contribution to the world."
Through their generous sponsorship of the Challenge, Amgen, Sanofi
Pasteur, the vaccines division of leading global pharmaceutical company
Sanofi, and Janssen Pharmaceutical Companies of Johnson & Johnson, are
taking an active role in changing and shaping the future of the
"Students are rapidly gaining interest in the sciences, and the
BioGENEius Challenge has found a way to encourage those students who are
excited about biotechnology to take the next step in their research,"
said Mark Lievonen, President of Sanofi Pasteur Limited. "We are
thrilled to participate in a program that cultivates young, innovative
minds to address our global challenges in new ways."
"Biotechnology offers an avenue to address some of the most pressing
issues of our time. Through the BioGENEius Challenge students gain an
appreciation for the fascinating aspects and tremendous potential of
scientific experimentation," added Jay P. Siegel, M.D., Chief
Biotechnology Officer and Head of Scientific Strategy and Policy for
Johnson & Johnson. "It is our expectation that this program will draw
bright young people into the endeavor of biotechnology and help
accelerate the development of the next-generation of scientists."
Wang's project was selected because her research focuses on developing
new fluorescent proteins used in the imaging of neural structures, the
visualization of cancer metastases and the monitoring of signaling
As the first place winner of the Amgen Bay Area BioGENEius challenge,
Wang will receive a $2,000 prize and a trip to the International
competition in San Diego. The first place winner in the International
competition will receive a $7,500 cash prize, the second place winner
will receive $5,000, the third place winner will receive $2,500 and the
fourth place winner will receive $1,000.
In addition to Sanofi Pasteur and Janssen, support for the BioGENEius
Challenge is provided by International Supporter: Genentech; and U.S.
National Supporters: Acorda Therapeutics, The Allergan Foundation,
Pfizer and Sangamo BioSciences. Amgen supports the Amgen Bay Area
Follow the BioGENEius Challenge: Throughout the challenge,
@BiotechInstitut will be tweeting interviews, photos, and engaging with
the biotechnology community by using the hashtag #BioGENEius.
BayBio provides comprehensive support and solutions tailored to the
unique needs of nearly 1000 Bay Area life science companies and
institutions, delivering tangible value through group purchasing
savings, capital access, government affairs & advocacy, networking and
best-practice sharing. Online at www.baybio.org.
Follow us on twitter: @BayBio.
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing,
manufacturing and delivering innovative human therapeutics. This
approach begins by using tools like advanced human genetics to unravel
the complexities of disease and understand the fundamentals of human
biology. Online at www.amgen.com.
About the Biotechnology Institute
The Biotechnology Institute is an independent, national nonprofit
organization dedicated to education about the present and future impact
of biotechnology. Its mission is to engage, excite and educate the
public, particularly students and teachers, about biotechnology and its
immense potential for solving human health, food and environmental
problems. For more information, visit www.biotechinstitute.org.
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has
core strengths in the field of healthcare with seven growth platforms:
diabetes solutions, human vaccines, innovative drugs, consumer
healthcare, emerging markets, animal health and the new Genzyme. Sanofi
is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1
billion doses of vaccine each year, making it possible to immunize more
than 500 million people across the globe. A world leader in the vaccine
industry, Sanofi Pasteur offers a broad range of vaccines protecting
against 20 infectious diseases. The company's heritage, to create
vaccines that protect life, dates back more than a century. Sanofi
Pasteur is the largest company entirely dedicated to vaccines. Every
day, the company invests more than EUR 1 million in research and
development. For more information, please visit: www.sanofipasteur.com
At Janssen we are dedicated to addressing and solving some of the most
important unmet medical needs of our time in oncology, immunology,
neuroscience, infectious diseases and vaccines, and cardiovascular and
metabolic diseases. Driven by our commitment to patients, we develop
innovative products, services and healthcare solutions to help people
throughout the world. For more information, please visit: www.janssenrnd.com
[ Back To Technology News's Homepage ]